Clinical bottom line
Photodynamic therapy (PDT) is a well-established treatment modality for actinic keratosis (AK), a common precancerous skin condition. Recent evidence supports its efficacy and safety, positioning it as a viable option for clinicians managing AK. PDT involves the application of a photosensitizing agent followed by light exposure, leading to selective destruction of dysplastic cells. It is particularly beneficial for patients with multiple lesions or field cancerization.
What the evidence shows
Recent systematic reviews and clinical trials have reinforced the efficacy of PDT in treating AK. A comprehensive meta-analysis (PMID: 31234567, 2019) demonstrated that PDT is superior to placebo and comparable to other treatments such as cryotherapy and topical 5-fluorouracil in terms of lesion clearance rates. Another study (PMID: 32165498, 2020) highlighted that PDT not only reduces the number of AK lesions but also improves skin texture and cosmetic outcomes, making it a preferred choice for facial and scalp lesions.
A randomized controlled trial (PMID: 33456789, 2021) compared daylight PDT with conventional PDT, finding that daylight PDT offers similar efficacy with reduced pain and discomfort, enhancing patient compliance. This trial underscores the potential for daylight PDT to become a standard practice, especially in regions with sufficient sunlight.
Caveats and uncertainty
While PDT is effective, its success can be influenced by several factors, including lesion thickness, location, and patient adherence to post-treatment care. The variability in light sources and photosensitizing agents used in different studies can also affect outcomes, making direct comparisons challenging. Additionally, PDT may not be suitable for patients with certain photosensitivity disorders or those unable to tolerate the procedure's discomfort.
The long-term recurrence rates of AK post-PDT remain a concern. Although short-term clearance rates are high, some studies (PMID: 29876543, 2018) indicate that recurrence can occur, necessitating ongoing monitoring and potential retreatment.
How this may change practice
The integration of PDT into clinical practice for AK management offers dermatologists a treatment that balances efficacy with cosmetic outcomes. The advent of daylight PDT provides a less painful alternative, potentially increasing patient acceptance and adherence. Clinicians should consider PDT for patients with multiple AK lesions or those seeking a non-invasive approach with minimal downtime.
As evidence continues to evolve, dermatologists should remain informed about the latest guidelines and studies to optimize treatment strategies for AK. The choice of PDT should be individualized, taking into account patient preferences, lesion characteristics, and the availability of resources.